NEW YORK (GenomeWeb News) — The National Institute of Mental Health plans to grant around $2 million to investigators who are studying ways to apply pharmacogenomics and personalized medicine technologies and techniques to the treatment of depression, the National Institutes of Health announced last week.
The goal of the project, which will support around seven researchers for up to three years, is to test new approaches and to develop models that will integrate specific patient characteristics into the treatment of depression.
NIMH said in a request for applications that the research can focus on, but is not limited to, analyzing databases for predicting treatment responses; identifying patients most likely to benefit from specific treatments; using pharmacogenomics studies to identify predictors of safety; matching patient types with treatment types; studying cost vs. benefit analysis of treatments; and developing statistical methods related to personalized treatment of depression.
Applications are due on June 20. More information can be found here.